加载中
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
常规交易时段
US$38.3503
+US$0.0703 · +0.18%
盘中时间采用ET。市场数据可能有所延迟。
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
日内区间
当前US$38.3503
52周区间
当前US$38.3503
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
65
低估
情绪
57
多空交织
风险
40
中等风险
动量
79
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
日内区间
当前US$38.3503
52周区间
当前US$38.3503
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.1亿 USD | 9039.8万 USD | 8271.3万 USD | 6435.7万 USD | 4804.2万 USD |
| 销货成本 | 1244.7万 USD | 888.1万 USD | 936.1万 USD | 765.4万 USD | 515.7万 USD |
| 毛利 | 9734.1万 USD | 8151.7万 USD | 7335.2万 USD | 5670.3万 USD | 4288.5万 USD |
| 研究与开发 | 6710.7万 USD | 5714.5万 USD | 4561.4万 USD | 5290.6万 USD | 4764.2万 USD |
| 销售、一般及管理费用 | 1.55亿 USD | — | 9327.4万 USD | 8283.8万 USD | — |
| 营业费用 | 2.22亿 USD | 1.78亿 USD | 1.39亿 USD | 1.36亿 USD | 1.35亿 USD |
| 利息收入 | 596.5万 USD | 890.1万 USD | 264.1万 USD | 93.8万 USD | 36.5万 USD |
| 利息支出 | 3384.8万 USD | 1252.1万 USD | 1471.5万 USD | 843.8万 USD | 1744.4万 USD |
| 折旧和摊销 | 241.1万 USD | 118.6万 USD | 170.5万 USD | 181.7万 USD | 177.3万 USD |
| 营业利润 | −1.25亿 USD | −9678.2万 USD | −6553.6万 USD | −7904.1万 USD | −9229.2万 USD |
| 净利润 | −1.53亿 USD | −1.27亿 USD | −1.02亿 USD | −1.1亿 USD | −1.11亿 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$56.60
上涨空间 47.59%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM4181.97万0.05%787.4亿 USD0.19%US$276.24-0.60%
iShares Russell 2000 Growth ETFIWO1299.27万0.09%139.17亿 USD0.24%US$350.71-0.85%
iShares Biotechnology ETFIBB1238.32万0.11%108.2亿 USD0.44%US$201.74-1.23%
Vanguard Russell 2000 ETFVTWO1054.67万0.06%180亿 USD0.06%US$111.58-0.62%
Fidelity Enhanced Small Cap ETFFESM781.32万0.12%64.1亿 USD0.28%US$44.995-0.54%
State Street SPDR Portfolio Developed World ex-US ETFSPDW688.9万0.02%406.96亿 USD0.03%US$49.625-0.12%
iShares Micro-Cap ETFIWC514.43万0.39%13.17亿 USD0.60%US$180.26-0.77%
Vanguard Health Care ETFVHT510.31万0.02%220亿 USD0.09%US$317.18-1.09%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMState Street SPDR Portfolio Developed World ex-US ETFSPDWiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
